Drug data last refreshed 3h ago · AI intelligence enriched 3w ago
Tubocurarine chloride is a neuromuscular blocking agent (NMB) used as an adjunct to anesthesia to facilitate intubation and provide skeletal muscle relaxation during surgery. It works by competitively blocking acetylcholine at the neuromuscular junction, preventing muscle contraction. This is a legacy small-molecule injectable approved in 1947.
As a 75-year-old product approaching loss of exclusivity with minimal linked roles, commercial team size is likely minimal and focused on defending residual market share rather than growth.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Zero linked jobs indicate minimal hiring activity and a shrinking career pipeline for this product. Working on tubocurarine as an early-career professional would offer limited visibility, constrained budget, and engagement primarily in defensive market maintenance rather than growth strategy.
Worked on TUBOCURARINE CHLORIDE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.